(Mapi Group) An ICON plc Company

Acquired by @ICONplc as of July 2017

[(Mapi Group) An ICON plc Company @Mapi_Global]

Thank you to all our followers, @MapiGlobal will no longer be updated. Please follow us at @ICONplc https://t.co/f8A4jHWZwC

[(Mapi Group) An ICON plc Company @Mapi_Global]

@ICONplc's rare disease clinical trials have led 9 drugs to market for #rarediseases in the past 5 years. Watch #ICONplc's short video here to learn more in support of @eurordis' #ShowYourRare #RareDiseaseDay 2019 campaign https://t.co/t2G0kY4Hy4

[(Mapi Group) An ICON plc Company @Mapi_Global]

There are over 6,000 #raredisease types. Learn more from #ICONplc @ICONplc this #RareDiseaseDay https://t.co/SPmNTFUx7W

[ICON Plc @ICONplc]

Wishing you happy holidays and a wonderful New Year. Best wishes from all @ICONplc https://t.co/cip4Q0GHaO

[(Mapi Group) An ICON plc Company @Mapi_Global]

Overcome the challenges of #oncology #clinicaltrials with @ICONplc's strategic approach https://t.co/uWRNbgDkG8

[(Mapi Group) An ICON plc Company @Mapi_Global]

@ICONplc expert, Dr. Andrew Roche, Ph.D., discusses overcoming challenges when developing #diabetes #clinicaltrials in this webinar https://t.co/RGHzIAgqkz

[(Mapi Group) An ICON plc Company @Mapi_Global]

Explore the key challenges of declining #researchanddevelopment (R&D) efficiency in this @ContractPharma article featuring ICON #thoughtleadership https://t.co/PYvBCW18gT

[(Mapi Group) An ICON plc Company @Mapi_Global]

Discover #bioanalyticalmethods that can be leveraged to add value in #earlyphase #clinicalstudies in @ICONplc's recent blog post https://t.co/eA0Gd705ZJ

[(Mapi Group) An ICON plc Company @Mapi_Global]

Making smarter, more timely decisions in #earlyphase #clinicaldevelopmentprogrammes can be achieved by adopting an #adaptivedesign. Discover how @ICONplc can help here https://t.co/o42k6T2TkQ

[(Mapi Group) An ICON plc Company @Mapi_Global]

@ICONplc has a team of experts who are dedicated to the #researchanddevelopment of #NASH #clinicaltrials. Learn how ICON has overcome common challenges in NASH trials by watching their recent webinar recording https://t.co/UUsOZ9hNvu

[(Mapi Group) An ICON plc Company @Mapi_Global]

Estimates show that #COPD will become the third leading cause of death by 2030, according to @WHO. Learn about @ICONplc’s #clinicaltrial solutions for the life-threatening #lungdisease here https://t.co/nQqgI7cSw7

[(Mapi Group) An ICON plc Company @Mapi_Global]

@ICONplc's laboratories’ testing capability and their clinical experience in more than 500 #oncologytrials makes them a trusted partner in your research. Learn more here https://t.co/LvtFXVhkCz

[(Mapi Group) An ICON plc Company @Mapi_Global]

‘Embracing #disruption for a new era in healthcare’ is the theme for this year’s Global @FT #Pharma & #Biotech Conference (London; 5-6 Nov). Request @ICONplc's 25% registration discount code today to signup to attend https://t.co/OmIcZ2mE46

[(Mapi Group) An ICON plc Company @Mapi_Global]

Discover how @ICONplc's experts met the first-patient-in goal for two non- #cysticfibrosis #bronchiectasis phase III #clinicalstudies https://t.co/2WYXdsIeXg

[(Mapi Group) An ICON plc Company @Mapi_Global]

Over the past 3 years, ICON has conducted 24 #respiratory clinical studies, which included 874 #clinicaltrial sites globally & more than 400 experienced respiratory team members. Learn more about @ICONplc's integrated approach to #pulmonary trials https://t.co/wD7B9lqmqG

[(Mapi Group) An ICON plc Company @Mapi_Global]

Approvals for #carttherapies are increasing & scaling up requires overcoming new challenges. Explore @ICONplc's potential solutions @ https://t.co/u6Yzif0jtK

[(Mapi Group) An ICON plc Company @Mapi_Global]

Learn how to enhance #patientoutcomes in #immunooncology #clinicaltrials with thoughtful planning & more treatment options in @ICONplc's white paper https://t.co/gvsjYHfWJo

[(Mapi Group) An ICON plc Company @Mapi_Global]

Discover @ICONplc's strategies for maintaining #clinicalsite relationships and enhancing #patientrecruitment in #IBD #clinicalstudies https://t.co/FYTIA5QXYd

[(Mapi Group) An ICON plc Company @Mapi_Global]

Explore @ICONplc's tailored solutions to #IBD #clinicaltrial #patientenrolment challenges in our phase 2a case study https://t.co/iregElVFj4

[(Mapi Group) An ICON plc Company @Mapi_Global]

@ICONplc has been shortlisted for the @Medtech_Insight #Medtech18 In Vivo Award for "Best Medtech Partnership/Alliance", recognising their work with the @bostonsci RM team & how they've set a new benchmark in partnering activity to-date. Learn more: https://t.co/bn5uIQcEp3